| Document |
Document Title |
|
WO/2019/156074A1 |
The present invention addresses the problem of providing a novel compound for the treatment and/or prevention of pain, which has excellent skin penetrability and is less irritative to the skin. The means for solving the problem is a comp...
|
|
WO/2019/144864A1 |
Provided are a glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the u...
|
|
WO/2019/145158A1 |
The present invention relates to the use of substituted bis-4H-pyranonyl compounds in which the 4H-pyranonyl units are combined with heteroalkyl groups, in detergents and cleaning agents, for improving detergent or cleaning performance w...
|
|
WO/2019/134667A1 |
A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically accep...
|
|
WO/2019/132784A1 |
This invention relates to a catalyst composition for a producing process of an unsaturated carboxylic acid salt and its derivatives from carbon dioxide and olefin, wherein the catalyst composition in the present invention has been proved...
|
|
WO/2019/121509A1 |
The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FT), (b) forming the crystalline compound according to formula (I)...
|
|
WO/2019/116069A1 |
The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.
|
|
WO/2019/111865A1 |
Provided is a method for producing a cyclic ether represented by formula (2), wherein a 2-hydroxy cyclic ether represented by formula (1) is reacted with hydrogen in the presence of a catalyst.
|
|
WO/2019/106122A1 |
The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.
|
|
WO/2019/104850A1 |
Disclosed is a method for preparing a lactone compound, for which a cyclic ketone compound serves as a raw material; in an oxygen-containing atmosphere, a cyclic organic nitroxide free radical serves as a catalyst, and a certain amount o...
|
|
WO/2019/090088A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/087145A1 |
Aromatic amides are described, having general formula (I), suitably substituted and having a high fungicidal activity, together with their use for controlling phytopathogenic fungi of important agricultural crops.
|
|
WO/2019/077106A1 |
The present invention relates to new compounds of general formula (I) showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channel...
|
|
WO/2019/068856A1 |
The present invention relates to aroma chemical compositions containing 3,5-diethyl-2-propyl-tetrahydropyran, a 3,5-diethyl-2-propyl-dihydropyran or a 3,5-diethyl-2-propyl-pyran, a mixture of such compounds, a stereoisomer of one of thes...
|
|
WO/2019/061299A1 |
Provided is a one-step amination reaction for producing an aminomethyl substituted heterocycloalkane, notably (tetrahydrofuran-2, 5-diyl) dimethanamine.
|
|
WO/2019/066467A1 |
Provided in the present invention are: a novel method for preparing a compound of chemical formula 1, comprising a step of obtaining a compound of chemical formula 1 by performing a reduction reaction on a compound of chemical formula 2;...
|
|
WO/2019/058890A1 |
The present invention provides an active light sensitive or radiation sensitive resin composition which has an excellent LER. Furthermore, provided are: a resist film; a method for forming a pattern; and a method for manufacturing an ele...
|
|
WO/2019/059555A1 |
Disclosed are: a trimethoxy phenyl compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof; and a composition for promoting hair growth or restoration, containing the same as an act...
|
|
WO/2019/039290A1 |
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition that has excellent resolution, exposure latitude, and pattern shape properties; and a resist film, a pattern-forming method, a method for producing an electr...
|
|
WO/2019/037862A1 |
The invention relates to organosulphur compounds which can be obtained from rose oxide, to methods for producing said organosulphur compounds and their use as odorants, flavourings or constituents of odorant mixtures and the products der...
|
|
WO/2019/035408A1 |
The present invention provides a method for producing a compound (i) having a group represented by a partial structure (A), a partial structure (AI), a partial structure (D), or a partial structure (DI), and a group represented by a part...
|
|
WO/2019/032936A1 |
Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the amino acid (southern) region. The lincosamides may have further modification at the C-1 and C-7 positions ...
|
|
WO/2019/032956A1 |
Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the C-7 position of the aminooctose (northern) region, thus distinguishing them from lincomycin and clindamyci...
|
|
WO/2019/032941A1 |
Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the amino acid (southern) region. The lincosamides may have further modification at the C-1 and C-7 positions ...
|
|
WO/2019/030284A1 |
The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in con...
|
|
WO/2019/022294A1 |
The present invention relates to a novel compound represented by following formula 2 produced by means of marine-derived fungus Penicillium sp. and a composition for improving skin wrinkles, enhancing elasticity and skin whitening using ...
|
|
WO/2019/015583A1 |
The present invention provides compounds of Formula (I) which can be used as ACC inhibitors and potently as therapeutic agents against diseases mediated by ACC.
|
|
WO/2019/016314A1 |
The present invention relates to an improved method for producing 3,7-dimethyl- 9-(2,6,6-trimethyl-1 -cyclohexen-1 -yl)-nona-2E,7E-dien-4-yne-1,6-diol.
|
|
WO/2019/009412A1 |
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...
|
|
WO/2019/008156A1 |
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-1/PD-L1 protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...
|
|
WO/2018/229013A1 |
The invention concerns a method for obtaining a free glucaric acid solution from a solution comprising non-free glucaric acid, water and at least one other constituent including at least one ion, characterised in that it comprises the fo...
|
|
WO/2018/226781A1 |
Disclosed are compositions containing at least 10% w/w or above of 1-O-gaHoyl-P-D-glucose (β-glucogallin) which additionally comprising of about 10% w/w to greater than 60% w/w total mucic acid gallates including mucic acid 1,4-lactone ...
|
|
WO/2018/215818A1 |
The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and...
|
|
WO/2018/213933A1 |
The present invention provides a method of preventing or treating atherosclerosis or a symptom thereof comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3); or a bis...
|
|
WO/2018/213150A1 |
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...
|
|
WO/2018/208985A2 |
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are ...
|
|
WO/2018/199798A1 |
The invention relates to the chemistry of organic compounds, pharmacology and medicine, and more particularly to developing and producing a novel medicinal agent for treating diseases caused by a human influenza virus. For this purpose, ...
|
|
WO/2018/201058A2 |
New 2-deoxy-2,3-dehydro-sialic acids and 2,7-anhydro-sialic acids, which are useful as sialidase inhibitors, and enzymatic methods for preparing them are disclosed. The methods include forming a reaction mixture comprising a glycoside ac...
|
|
WO/2018/193273A1 |
The invention provides novel analogues of enacyloxin Ha and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negat...
|
|
WO/2018/189060A1 |
The invention comprises novel chiral metal complex compounds of the formula (I) wherein M, PR2, R3 and R4 are outlined in the description, its stereoisomers, in the form as a neutral complex or a complex cation with a suitable counter io...
|
|
WO/2018/163194A1 |
The present invention relates to a process for the preparation of D-glucitol, 1,5- anhydro-1-C-[4-chloro-3-[[ 4-[[(3S)-tetrahydro-3-furanyl)oxy )phenyl] methyl]phenyl]-, (IS) formula-1.
|
|
WO/2018/161022A1 |
The present disclosure provides solid forms, including a salt or co-crystal, of Compound I which exhibits Acetyl-CoA carboxylase ("ACC") inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are pr...
|
|
WO/2018/150421A1 |
The invention provides efficient cyclization processes of hydroxyalkenoic acids and products produced therefrom. The following reactions are claimed: Formula (I), (II), (V) and (VI).
|
|
WO/2018/149991A1 |
The present invention relates to particular sulfonamide derivatives, the pharmaceutically acceptable addition salts thereof, the hydrates thereof and/or the solvates thereof, and also the use thereof as inverse agonists of retinoid-relat...
|
|
WO/2018/146285A1 |
The present invention relates to a method for the production of organo-iodinated compounds, as well as the production intermediates thereof. More specifically, the present invention relates to a method for the production of organo-iodina...
|
|
WO/2018/145653A1 |
The present invention relates to the technical field of chemical medicine and relates to a compound represented by formula (I) or formula (II) and a preparation method therefor, the compound being a biaryl derivative and having retinoid-...
|
|
WO/2018/142422A1 |
The present invention discloses a novel process for the preparation of Dapagliflozin (S)-propylene glycol hydrate of Formula II. (Formula II)
|
|
WO/2018/135822A1 |
The present invention relates to: an additive for a non-aqueous electrolyte, the additive enabling the formation of a stable film on an electrode surface and inhibiting the generation of metallic foreign bodies causing side-effects withi...
|
|
WO/2018/130625A1 |
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...
|
|
WO/2018/130155A1 |
Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a ...
|
